Bristol-Myers Squibb BMY Alliance revenues — Total Revenues

Other product segments

Similar metrics at other companies

NWETotal Revenue — Total Revenues

$497.57M+6.6%

ACNConsulting Revenue — Total Revenues

$9.33B+3.6%

CMEOther Revenue — Total Revenues

$115.6M+9.2%

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

AEPOther Revenues — Total Revenues

$158M+19.7%

AEPTransmission Revenues — Total Revenues

$110M+3.8%

FAQ

What is Bristol-Myers Squibb's alliance revenues — total revenues?

Bristol-Myers Squibb (BMY) reported alliance revenues — total revenues of $104M in Q2 2026.

How has Bristol-Myers Squibb's alliance revenues — total revenues changed year-over-year?

Bristol-Myers Squibb's alliance revenues — total revenues decreased by 12.6% year-over-year, from $119M to $104M.

What is the long-term trend for Bristol-Myers Squibb's alliance revenues — total revenues?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's alliance revenues — total revenues has grown at a -11.1% compound annual growth rate (CAGR), from $716M to $447M.

What does alliance revenues — total revenues mean?

This metric represents the portion of total revenue generated through collaborative arrangements and partnerships with other pharmaceutical or biotechnology companies. It reflects income derived from co-promotion agreements, profit-sharing models, or licensing deals where the company shares development and commercialization responsibilities. These revenues are critical for assessing the company's ability to leverage external expertise and market access to supplement its internal drug pipeline.